
Presented by Dr. Cesar Perez, this first-in-human phase 1 study of BG-C9074—a B7-H4–targeting antibody-drug conjugate—demonstrated early antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors.

Your AI-Trained Oncology Knowledge Connection!


Presented by Dr. Cesar Perez, this first-in-human phase 1 study of BG-C9074—a B7-H4–targeting antibody-drug conjugate—demonstrated early antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors.

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.

Published: January 19th 2022 | Updated:

Published: June 23rd 2025 | Updated: